Back to Journals » Breast Cancer: Targets and Therapy » Volume 2

Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane

Authors Macpherson IR, Lindsay C, Canney P

Published 14 October 2010 Volume 2010:2 Pages 59—70

DOI https://doi.org/10.2147/BCTT.S11835

Review by Single anonymous peer review

Peer reviewer comments 4



Iain RJ Macpherson1,3, Colin Lindsay2, Peter Canney3

1Centre for Oncology and Applied Pharmacology, University of Glasgow, Glasgow, Scotland, UK; 2Beatson Institute for Cancer Research, Glasgow, Scotland, UK; 3Beatson West of Scotland Cancer Centre, Glasgow, Scotland, UK

Abstract: Adjuvant hormonal therapy significantly reduces the risk of recurrence and death following surgery for estrogen receptor (ER)-positive early breast cancer. Previously, the gold standard hormonal therapy was tamoxifen, a selective modulator of the ER. However, large clinical trials conducted over the past decade have defined the efficacy of an alternative class of hormonal agent, namely the third-generation aromatase inhibitors (AIs): exemestane, letrozole, and anastrozole. On the basis of the pivotal International Exemestane Study (IES), exemestane, a steroidal third-generation AI, was licensed for the adjuvant treatment of postmenopausal women with ER-positive early breast cancer following 2–3 years of tamoxifen to complete a total of 5 years of adjuvant hormonal therapy. Here, we consider recent data to emerge primarily from the IES and Tamoxifen Exemestane Adjuvant Multicenter trials and consider their implications for the role of exemestane in the adjuvant treatment of breast cancer.

Keywords: breast cancer, exemestane, aromatase, tamoxifen

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.